VEGFA and heart failure: A meta-analysis of all VEGF-TKI agents tempered the attributable risk and identified the risk for heart failure as 3.2% for the group, with a significant odds ratio of 2.4.145 One should remember that the real risk of these drugs is underestimated since they are mainly given for patients with metastatic disease, and therefore longitudinal long-term surveillance of their detrimental effects is impossible.